ABSTRACT
Primary adrenal epithelioid sarcoma is a rare lesion of the adrenal gland, and only seven cases have been reported in the domestic and international literature to date. We herein report a case involving a 65-year-old man with primary adrenal epithelioid sarcoma. After being admitted to the hospital with an adrenal mass found on physical examination, the patient underwent laparoscopic right adrenalectomy. Postoperative pathological findings indicated an epithelioid sarcoma (proximal type). Primary adrenal epithelioid sarcoma is a rare malignancy. Diagnosis is challenging and relies on histopathology and immunohistochemical staining.
Subject(s)
Biomarkers, Tumor , Sarcoma , Male , Humans , Aged , Immunohistochemistry , Sarcoma/diagnosis , Sarcoma/surgery , Sarcoma/pathologyABSTRACT
We aimed to investigate the diagnostic value of urinary Tamm-Horsfall protein (THP) and 24 h urine osmolality for recurrent calcium oxalate (CaOx) stones. Clinical data of 120 patients with upper urinary tract stones admitted to our hospital between January 2020 and January 2022 were retrospectively reviewed. Patients were divided into recurrence (53 patients) and non-recurrence (67 patients) groups based on postoperative stone recurrence. Meanwhile, 50 healthy patients were selected as the control group. Urinary THP levels, 24 h urine osmolality, and biochemical indices were compared between the three groups; their diagnostic values for stone recurrence were evaluated using receiver operating characteristic (ROC) curves. Urinary THP, 24 h urine osmolality, and biochemical indices were significantly higher in the recurrence group than in the non-recurrence and control groups (P < 0.05). The 24 h urine osmolality was positively correlated with urinary oxalic acid and calcium excretion. ROC curve analysis showed that optimal cutoff values of urinary THP and 24 h urine osmolality for the diagnosis of stone development were ≥27.01 mg/L and ≥577.69 mOsm/(kg H2O), respectively. Furthermore, these indices combined significantly improved the accuracy of diagnosis. Urinary THP and 24 h urine osmolality were higher in patients with recurrent CaOx stones. Detection of both parameters combined can accurately diagnose stone recurrence.
ABSTRACT
Introduction: The aim of this study was to explore the clinical effect of transurethral columnar balloon dilation of the prostate (TUCBDP), in the treatment of benign prostatic hyperplasia in men over the age of 60 years old. Methods: This was a retrospective multi-center study follow-up of patients with benign prostatic hyperplasia (BPH) who underwent TUCBDP. The international prostate symptom score (IPSS), quality of life score (QoL), residual urine volume (PVR), andmaximum urine flow rate (Qmax) were evaluated one and six months after the procedure. Results: All 68 patients had the operation from January 2019 to December 2021. Their postoperative IPSS, QoL, PVR, andQmax of the patients significantly improved, in comparison to before procedure (p < 0.05). The improvement rate of IPSS andQoL in the small volume BPH group was significantly higher than that in the non-small volume BPH group (p < 0.05), but had little effect on the improvement rate of PVR and Qmax. Conclusions: TUCBDP can significantly improve IPSS, QoL, PVR, and Qmax in elderly men with BPH up to six months after theprocedure, with the advantages of shorter operation time and less blood loss. The postoperative improvement effect of patientswith small volume BPH was more obvious than that of patients with non-small volume BPH (AU)
Subject(s)
Humans , Male , Middle Aged , Prostatic Hyperplasia/therapy , Dilatation/methods , Retrospective Studies , Follow-Up StudiesABSTRACT
INTRODUCTION: The aim of this study was to explore the clinical effect of transurethral columnar balloon dilation of the prostate (TUCBDP), in the treatment of benign prostatic hyperplasia in men over the age of 60 years old. METHODS: This was a retrospective multi-center study follow-up of patients with benign prostatic hyperplasia (BPH) who underwent TUCBDP. The international prostate symptom score (IPSS), quality of life score (QoL), residual urine volume (PVR), and maximum urine flow rate (Qmax) were evaluated one and six months after the procedure. RESULTS: All 68 patients had the operation from January 2019 to December 2021. Their postoperative IPSS, QoL, PVR, and Qmax of the patients significantly improved, in comparison to before procedure (p < 0.05). The improvement rate of IPSS and QoL in the small volume BPH group was significantly higher than that in the non-small volume BPH group (p < 0.05), but had little effect on the improvement rate of PVR and Qmax. CONCLUSIONS: TUCBDP can significantly improve IPSS, QoL, PVR, and Qmax in elderly men with BPH up to six months after the procedure, with the advantages of shorter operation time and less blood loss. The postoperative improvement effect of patients with small volume BPH was more obvious than that of patients with non-small volume BPH.
